E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 11/4/2005 in the Prospect News Biotech Daily.

Jefferies cuts SFBC's price target to $35

SFBC International, Inc. was maintained by Jefferies & Co. Inc. at a buy rating with a reduced price target of $35 from $46 after third-quarter results showed weak new business. Also, recent negative press led to a massive sell-off of the stock Thursday, which was a loud vote of low confidence, Jefferies said. Transparency has been poor, causing explainable, but unusual, moves in margins and tax rate to produce exacerbated reactions. Shares of the Miami drug development services company were up $0.54, or 1.93%, at $28.45 on volume of 2,501,056 shares versus the three-month running average of 314,636 shares.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.